David Lebowitz
Stock Analyst at Citigroup
(3.50)
# 896
Out of 5,241 analysts
119
Total ratings
60.92%
Success rate
15.22%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $75.68 | +10.99% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $78.64 | +6.82% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $32.45 | +47.92% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $12.62 | +58.48% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $245.49 | +18.13% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $97.63 | +5.50% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $31.71 | +19.84% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $34.19 | -35.65% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $69.66 | -3.82% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $51.10 | +9.59% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $13.09 | -23.61% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.17 | +28.76% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $72.72 | -38.12% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $111.39 | -38.95% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $539.89 | -29.24% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $53.24 | +80.32% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $5.14 | +133.46% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $293.45 | -44.11% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $21.57 | +80.81% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $20.55 | +2.19% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $8.90 | +4,450.56% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.67 | +281.47% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $75.68
Upside: +10.99%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $78.64
Upside: +6.82%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $32.45
Upside: +47.92%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $12.62
Upside: +58.48%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $245.49
Upside: +18.13%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $97.63
Upside: +5.50%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $31.71
Upside: +19.84%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $34.19
Upside: -35.65%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $69.66
Upside: -3.82%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $51.10
Upside: +9.59%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $13.09
Upside: -23.61%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.17
Upside: +28.76%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $72.72
Upside: -38.12%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $111.39
Upside: -38.95%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $539.89
Upside: -29.24%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $53.24
Upside: +80.32%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $5.14
Upside: +133.46%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $293.45
Upside: -44.11%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $21.57
Upside: +80.81%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $20.55
Upside: +2.19%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $8.90
Upside: +4,450.56%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.67
Upside: +281.47%